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ABSTRACT:
Multiparous Stat1-/- mice spontaneously develop mammary tumors with increased 
incidence: at an average age of 12 months, 55% of the animals suffer from mammary 
cancer, although the histopathology is heterogeneous. We consistently observed 
mosaic expression or down-regulation of STAT1 protein in wild-type mammary cancer 
evolving in the control group. Transplantation experiments show that tumorigenesis 
in Stat1-/- mice is partially influenced by impaired CTL mediated tumor surveillance. 
Additionally, STAT1 exerts an intrinsic tumor suppressing role by controlling and 
blocking proliferation of the mammary epithelium. Loss of STAT1 in epithelial cells 
enhances cell growth in both transformed and primary cells. The increased proliferative 
capacity leads to the loss of structured acini formation in 3D-cultures. Analogous 
effects were observed when Irf1-/- epithelial cells were used. Accordingly, the rate 
of mammary intraepithelial neoplasias (MINs) is increased in Stat1-/- animals: MINs 
represent the first step towards mammary tumors. The experiments characterize 
STAT1/IRF1 as a key growth inhibitory and tumor suppressive signaling pathway that 
prevents mammary cancer formation by maintaining growth control. Furthermore, 
they define the loss of STAT1 as a predisposing event via enhanced MIN formation.
INTRODUCTION
The signal transducers and activators of transcription 
(STATs) are an intensely studied family of transcription 
factors that have been recognized as critical mediators of 
cytokine and growth factor receptor signaling, required 
for cell proliferation, survival and differentiation [1, 2]. 
Activation of STATs is frequently observed in different 
cancer entities and it has been postulated that deregulation 
of these factors may be involved in tumorigenesis. 
STAT1 is constitutively expressed throughout the entire 
development of the mammary gland. Its phosphorylation 
pattern – elevated in virgin glands, low throughout 
gestation and lactation, rising again at late involution – Oncotarget 2011; 2:  1043 - 1054 1044 www.impactjournals.com/oncotarget
is unique, although the exact function of phosphorylation 
is unclear [3]. STAT1 is expressed in the epithelial 
compartment of the mammary gland, suggesting it has an 
active role in epithelial cells [4]. STAT1 is of particular 
interest in mammary cancer as it is known to possess 
an independent prognostic significance in human breast 
cancer: high activation of STAT1 has been reported to 
correlate with an overall longer and relapse-free survival 
[5, 6]. Furthermore, treatment of human mammary tumor 
cells with cytostatic drugs has been shown to induce 
STAT1 activation, resulting in enhanced apoptosis [7, 8]. 
Recent work in mouse models of neu/ERBB2-induced 
breast cancer has underlined STAT1’s tumor suppressive 
role [9, 10]. By crossing Stat1fl/fl mice with MMTV-neu-
IRES-cre mice, Klover et. al. showed that tumor onset is 
significantly accelerated in Stat1fl/fl x MMTV-neu-IRES-cre 
mice compared to STAT1-expressing wild-type controls. 
This conclusion suggests that STAT1 has an autonomous 
role in neu/ERBB2-induced mammary tumor formation. 
The second report did not discriminate between the 
intrinsic and the immunological contribution of STAT1-
deficiency but came nevertheless to the conclusion that 
Stat1-/-  x  ERBB2/neu mice develop mammary tumors 
significantly faster than control mice. Together, the studies 
unequivocally defined STAT1 as a tumor suppressor in 
mammary cancer.
STAT1’s tumor suppressing properties may be 
related to cell-intrinsic effects as STAT1 has been shown 
to block proliferation and to be involved in the induction 
of apoptosis [11-15]. Furthermore, Stat1-/- mice have a 
severely compromised immune system due to their lack of 
IFN-signaling [16, 17] as well as to an impaired cytotoxic 
NK-cell and CTL capacity [18, 19]. The contributions 
of these different components to mammary tumor 
surveillance are to date poorly understood. Moreover, 
all previous studies have been based on oncogene-driven 
mammary tumor formation in the absence of STAT1. 
We  now  report  for  the  first  time  that  loss  of 
STAT1 alone is sufficient to cause pregnancy-associated 
mammary cancer in BALB/c mice, independent of any 
other transgenic oncogene. By transplanting Stat1-/- 
mammary glands into wild type recipient mice and vice 
versa we reveal that STAT1 contributes to the formation 
of mammary tumors through cell-intrinsic as well as 
immunological activities. Stat1-/- mammary epithelial cells 
exhibit enhanced proliferation, which might facilitate 
the development of mammary intraepithelial neoplasias 
(MINs) and subsequently also invasive mammary tumors. 
We suggest that STAT1/IRF1 acts in a linear axis to block 
growth. It is known that cytotoxic T-cells are impaired in 
Stat1-/- mice and we also characterize cytotoxic T-cells as 
major mediators of mammary tumor surveillance. 
RESULTS
STAT1 deficiency is sufficient to cause mammary 
cancer
BALB/c mice are predisposed to develop mammary 
tumors and are therefore suitable to study spontaneous 
mammary tumorigenesis [11]. To evaluate the role of 
STAT1 in the spontaneous development of mammary 
tumors we crossed Stat1-/- mice into the BALB/c genetic 
background. Groups of wild-type BALB/c and Stat1-/-/c 
female mice were kept under breeding conditions and 
regularly controlled by palpation for mammary tumor 
formation. Within an average of one year, 55% of the 
multiparous  Stat1-/- mice had developed mammary 
tumors. In the control group, only 10% had mammary 
tumors and disease onset was significantly later (Stat1-/-: 
394.5 days ± 13.52 and Stat1+/+: 479.3 days ± 11.46; **P 
= 0.0089; values represent mean ± SEM) (Fig. 1A and 
1B). No mammary tumors were detected in wild-type or 
Stat1-/- nulliparous animals over a period of 20 months. 
Interestingly, all tumors that evolved in wild-type mice 
showed a mosaic expression and partial down-regulation 
of STAT1 protein (Fig. 1C). Loss or down-regulation of 
STAT1 was restricted to tumor cells and was not observed 
in the normal mammary tissue surrounding the cancer.
Mammary  epithelial  transplantation  uncovers 
a  mammary  gland  cell-intrinsic  and  an 
immunological  contribution  of  STAT1  to  the 
development of mammary tumors
To test whether these results stemmed from an 
intrinsic action of STAT1 within the mammary epithelium 
rather than simply being related to tumor-promoting 
changes triggered by the impaired immune system of the 
Stat1-/- animals, we transplanted Stat1-/- mammary epithelial 
tissue into the cleared fat pad of the 4th mammary gland of 
Stat1+/+ mice, and vice versa (see scheme in Fig. 1D). To 
control for tumor onset provoked by the transplantation 
procedure itself, we additionally transplanted Stat1+/+ 
mammary tissue into Stat1+/+ mice. Moreover, a group of 
Stat1-/- mice was maintained under identical conditions 
in a non-transplanted setting. All animals were bred 
constantly to accelerate mammary tumor development. 
Animals  were  sacrificed  when  any  evolving  mammary 
tumor reached a diameter of one centimeter or earlier if 
there were signs of disease such as weight loss, scrubby 
fur or reduced mobility. All transplanted mammary glands 
– irrespective of whether a visible tumor had evolved 
– were subjected to histological analysis to assess the Oncotarget 2011; 2:  1043 - 1054 1045 www.impactjournals.com/oncotarget
Figure 1: (A-C) Loss of STAT1 increases incidence and decreases latency of mammary tumors. (A) Incidence and (B) 
latency of spontaneously occurring, parity-induced mammary tumors in Stat1+/+ (n=30) and Stat1-/- (n=20) mice. Tumor development was 
monitored for up to 20 months. (C) STAT1-stained histological sections of a normal mammary gland from a multiparous wild type mouse 
after involution (upper panel) and of Stat1+/+ mammary tumors (bottom panel). Stat1+/+ tumors display mosaic expression and partial 
downregulation of STAT1 protein. The arrow indicates a vascular invasion. Scale bars: 100 µm. (D-F) Absence of STAT1 in the immune 
system and also in the mammary gland tissue influences mammary tumor formation. (D) Experimental setup of mammary gland 
transplantation experiment. Mammary gland tissue of Stat1-/- mice was transplanted into the cleared fat pad of the 4th mammary gland of 
Stat1+/+ mice (n=27), or Stat1+/+ mammary glands were transplanted into Stat1-/- animals (n=22). Control groups: Stat1+/+ tissue transplanted 
into Stat1+/+ animals (n=9), non-transplanted Stat1-/- animals (n=13). Mice were bred constantly and checked for mammary tumor growth 
for up to 20 months. On average, each animal had 7 litters. (E) Incidence and (F) latency of spontaneously occurring, parity-induced 
mammary tumors in all mice in the transplantation experiment. Tumors were classified into four groups: Stat1+/+ tumors in Stat1+/+ mice, 
Stat1+/+ tumors in Stat1-/- mice, Stat1-/- tumors in Stat1-/- mice and Stat1-/- tumors in Stat1+/+ mice. 
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success of the transplantation procedure and to study 
spontaneous tumorigenesis.
Immunohistochemical staining for STAT1 revealed 
a successful outgrowth in 36% of Stat1-/- donor tissue in 
Stat1+/+ recipient mice upon transplantation, whereas in the 
Stat1+/+ => Stat1+/+ setting the take rate reached 90% (Fig. 
S1A and S1B). FACS analysis did not show any significant 
differences in mammary stem cell populations between 
wild type and Stat1-/- animals, eliminating the possibility 
that this cell compartment contributed to the repopulation 
frequency (Fig. S2A). The analysis of freshly transplanted 
mammary glands uncovered a dense infiltration with CD3+ 
T-lymphoid cells and NKp46+ NK-cells, irrespective 
of the genotype (Fig. S2B). Although we used syngenic 
mice in the experiment – all animals were back-crossed to 
BALB/c – an inflammatory infiltrate is unavoidable due 
to tissue damage during the transplantation procedure. We 
assumed that Stat1-/- mice accepted the transplanted tissue 
better due to their partially impaired immune system.
Spontaneous tumor development was monitored over 
a period of 20 months in our cohort of transplanted animals. 
STAT1 expression was surveyed by immunohistochemical 
staining and PCR-analysis. Non-transplanted mammary 
glands where analysed for tumor development and served 
as an internal control. The observed tumor incidence and 
latency are summarized in Figs 1E and 1F. Spontaneous 
tumors developed within 20 months from non-transplanted 
tissue in 19/35 (54%) of the Stat1-/- mice and in 4/36 (11%) 
of the Stat1+/+ mice. During this time, 3/22 (14%) of the 
Stat1-/- animals displayed tumors that originated from 
the transplanted Stat1+/+ mammary glands. Even when 
adjusted for the success rate of transplantation (90%), 
the tumor incidence did not exceed 15% in this group. 
In the reverse experiment, 3/27 Stat1-/- tumors evolved 
in Stat1+/+ mice, translating into a 30% tumor incidence 
after adjustment for the significantly lower transplantation 
success rate.
In summary, our observations enable us to conclude 
that STAT1 suppresses tumor formation in the mammary 
epithelial cells themselves. Tumor incidence increases 
upon transplantation of Stat1-/- mammary glands into 
Stat1+/+ recipients compared to a Stat1+/+ => Stat1+/+ 
scenario (30% versus 11%). We also deduce that the 
STAT1-deficient  immune  system  contributes  to  and 
accelerates carcinogenesis. Stat1+/+ as well as Stat1-/- 
mammary tumors occurred with an increased incidence in 
a Stat1-/- environment compared to in Stat1+/+ surroundings 
(15% versus 11% for Stat1+/+ tumors; 54% versus 30% 
for  Stat1-/- tumors). Consistently, tumor development 
occurred with a significantly shorter latency in a Stat1-/- 
environment, irrespective of whether spontaneous tumor 
development or carcinomas evolving after transplantation 
are compared (Fig. 1F).
Loss of STAT1 favors mammary intraepithelial 
neoplasias (MINs)
An overview of the histopathological and 
immunohistochemical features of the tumors that arose 
in our animal cohort is provided in Table I. Fig. 2A 
depicts representative panels of the immunohistochemical 
characterization of two Stat1+/+ and two Stat1-/- tumors. 
The tumors were characterized either as neoplasisas in 
situ  (mammary intraepithelial neoplasia, MIN) or as 
invasive ductal carcinomas. No lobular carcinomas were 
diagnosed. Grading was performed according to Elston 
and Ellis [20]. Invasive features were present in 62% of all 
Stat1-/- and in 80% of all Stat1+/+ tumors. We did not detect 
any genotype-related pattern with regard to grading of 
tubule formation, nuclear polymorphism or mitotic count. 
However, we found a high incidence of MIN (8/13) in 
Stat1-/- tumors: 4 of low grade and 4 of high grade (Table 
I). In contrast, 2/5 Stat1+/+ tumors displayed only low-
grade MINs and no high-grade MIN could be detected. 
Importantly, the two cases of MIN detected in Stat1+/+ 
mice had largely lost STAT1 protein expression (Fig. 2B). 
These observations revealed an increased incidence of 
MIN upon loss of STAT1.
The STAT1/IRF1 axis is implicated as having an 
important role in MIN formation, regulating the 
proliferation of mammary epithelial cells
Loss of the STAT1 downstream transcription factor 
IRF1 has been reported in MIN cases of human breast 
cancer [21]. Moreover, the loss of heterozygosity at the 
IRF1 gene locus has been found to be a frequent event 
in human breast cancer [22]. It thus seems possible that 
STAT1 and IRF1 act in a common axis to suppress MIN 
and subsequently mammary tumor formation [23, 24]. 
Initial evidence for this hypothesis was provided by 
the analysis of STAT1 and IRF1 protein expression in 
primary mouse mammary tumor tissue: the levels of IRF1 
protein correlated with the expression levels of STAT1. 
Furthermore, IRF1 expression in Stat1-/- tumors was shown 
to be low (Fig. 3A). To evaluate whether both Stat1-/- and 
Irf1-/- mice are predisposed to develop mammary tumors, 
whole mounts of mammary glands were analyzed. It was 
noteworthy that already at the virgin state Stat1-/- and Irf1-
/- mice displayed an increased amount of ductal structure 
compared to wild-type controls (Fig. 3B and S3), although 
MIN could not be detected at that age in these Stat1-/- and 
Irf1-/- mice.
To investigate the role of STAT1 and IRF1 in MIN 
formation, we employed an in vitro three-dimensional 
culture system, which allowed us to monitor the formation 
of polarized acini from single mammary epithelial cells 
[25]. Mammary epithelial cells were prepared from 
glands of 6- to 8- week-old virgin wild-type, Stat1-/- Oncotarget 2011; 2:  1043 - 1054 1047 www.impactjournals.com/oncotarget
and Irf1-/- mice and analyzed in this 3D culture system. 
Acini developed irrespective of the genotype and with 
no significant difference in total volumes of the spheres 
(Fig. S4). Remarkably, Stat1-/- and Irf1-/- acini displayed a 
significantly higher cellularity at all time points compared 
to wild-type controls (Figs 3C, top panel and 3D). Whereas 
mammospheres of wild-type controls were formed by a 
single monolayer, immunofluorescent staining showed a 
less organized cell array and partial epithelial bi-layering 
in Stat1-/- and Irf1-/- spheres (Fig. 3C, bottom panel and 
Videos S1A, B and C). The increased cellularity could 
not be attributed to decreased apoptosis as there were 
no detectable signs of cleaved caspase-3 activity, even 
at early time points (day 2) when the lumen of the acini 
starts to evolve (Fig. S5). This finding is in line with the 
observations made by Jechlinger [25], who described 
that lumina form without epithelial cells undergoing 
apoptosis. The polarity of the Stat1-/- and Irf1-/- acini was 
unaltered as staining for the basal marker Integrin α6 did 
not reveal any major changes. Furthermore, we failed to 
detect any changes in the formation of tight junctions 
by staining for Zona Occludens-1 (ZO1), a protein that 
binds  directly  to  occludins  and  is  a  bona  fide  marker 
for tight junctions (Fig. 3C, bottom panel). However, 
examining  BrdU  incorporation  revealed  a  significantly 
increased proliferation rate in Stat1-/- and Irf1-/- spheres 
Figure 2: (A) Both, Stat1+/+ and Stat1-/- mammary tumors are heterogenous. Representative pictures of immunohistochemical 
characterization of two Stat1+/+ (top panel) and two Stat1-/- mammary tumors (bottom panel). Scale bars: 100 µm. (B) Loss of STAT1 
correlates with MIN formation. Representative pictures of immunohistochemical characterization of one low-grade Stat1+/+ (left panel) 
and one high-grade Stat1-/- MIN (right panel). Stat1+/+ MINs display down-regulation of STAT1 protein, as indicated by the arrow. Scale 
bars: 100 µm; ERα: estrogen receptor alpha; CK8: cytokeratin 8.
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Figure 3: (A, B) Loss of STAT1 might cause mammary tumor formation by down-regulating IRF1. (A) Western blotting of 
mammary tumor samples. Low expression of IRF1 protein correlates with STAT1 expression. (B) Representative pictures of whole mounts 
of mammary glands from 50 day-old virgin wild-type (wt), Stat1-/- and Irf1-/- mice. Stat1-/- and Irf1-/- glands show an increased density 
of ductal structures but no differences in end duct formation. Scale bars: 0.5 cm, 500 µm, 100 µm. LN: lymph node. (C-F) Mammary 
epithelial cells of Stat1-/- and Irf1-/- mice show enhanced proliferation. (C+D) In a 3D culture assay, primary mammary epithelial cells 
derived from Stat1-/- and Irf1-/- mice formed spheres with increased cellularity compared to wild-type controls. (C) Representative bright-
field microscopy pictures (top panel) and fluorescence microscopy pictures (bottom panel) from 8 day-old spheres of different genotypes. 
(Blue) DAPI; (red) Integrin α6; (green) ZO1. Scale bars: 50 µm. (D) Cellularity of spheres was measured at different time points. For details 
of calculations see SI Materials and Methods. n ≥ 33 per genotype. (E+F) To measure proliferation, spheres were exposed to BrdU for 
24h, before fixation. (E) Representative fluorescence microscopy pictures of 6 day-old spheres derived from wt, Stat1-/- and Irf1-/- epithelial 
cells. (Blue) DAPI; (red) anti-BrdU. Scale bars: 50 µm. (F) Percentage of BrdU-positive cells was calculated at different times of growth. 
n ≥ 18; 1 n = 1 sphere. (D+F) Statistical analysis: asterisks represent significances to the wild type. No significant differences could be 
detected between any Stat1-/-/Irf1-/- pair. Data are representative of three independent experiments. (G) To measure proliferation in vivo, 
BrdU was injected intraperitoneally into mice. Mammary gland cells were isolated and percentages of BrdU-positive mammary gland cells 
after 3 days of BrdU administration were measured using the BD FACS-Canto II FACS device with the BD FACS Diva software (Beckton 
Dickinson). n = 3 per genotype. 
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compared to wild type controls in vitro (Fig. 3E and 3F). 
This was confirmed by analysis of mammary epithelial 
proliferation in vivo. For this purpose, BrdU was injected 
intraperitoneally into mice for a period of 3 days. Isolated 
mammary glands were digested and cells in single-
cell suspensions were stained with anti-BrdU antibody. 
Quantification of BrdU-positive cells by flow cytometry 
confirmed the enhanced proliferation of Stat1-/- and Irf1-/- 
mammary epithelial cells (Fig. 3G).
Mammary tumor formation is under the control 
of cytotoxic T-lymphocytes (CTLs)
Our transplantation studies revealed that the absence 
of STAT1 from the immune system significantly enhances 
tumor incidence and shortens the latency of mammary 
tumor formation. STAT1 is believed to have an essential 
role in CTL- and NK-cell cytotoxicity; both lymphoid 
lineages are important mediators of tumor surveillance. 
Immunohistochemical staining for CD3 and NKp46 
verified a dense infiltration of all mammary tumors with 
cytotoxic T-cells, whereas in all tumors NK-cells were 
rare and not consistently detectable (Fig. 4A). To clarify 
the contribution of NK and/or cytotoxic T cells to tumor 
surveillance, we generated mammary tumor cell lines. 
Four cell lines (#1, #2: Stat1-/-; #3, #4: Stat1+/+) were 
established during the course of our study, all of which 
displayed an epithelial-like phenotype (Fig. 4B). Of note, 
cell lines lacking STAT1 had a proliferative advantage in 
vitro and in vivo over Stat1+/+ lines (Fig. 4C and S6A-C). 
5x105 cells were orthotopically injected into the mammary 
Number
Genotype
Tumor
Genotype
Mouse
Histological Classification
Invasiveness
MIN ERa HER2
Tubule
formation
Nuclear
pleomorphism
Mitosis
count
Grading
1 Stat1-/- Stat1-/- ductal/with medullary features 3 3 3 3 - 0 0
2 Stat1-/- Stat1-/- ductal 2 2 1 1 - 0 0
3 Stat1-/- Stat1-/- ductal 3 3 3 3 - 0 0
4 Stat1-/- Stat1-/- ductal 2 3 3 3 high grade 4(60%/2) 1
5 Stat1-/- Stat1-/- ductal 3 3 3 3 high grade 3(30%/1) 0
6 Stat1-/- Stat1-/-
ductal/with metaplastic 
features
3 3 2 3 high grade 3(20%/1) 0
7 Stat1-/- Stat1-/- intraductal with microinvasion low grade 0 1~2
8 Stat1-/- Stat1-/- intraductal-papillary low grade 3(10%/1) 0
9 Stat1-/- Stat1-/- intraductal with microinvasion low grade 3(50%/1) 0
10 Stat1-/- Stat1-/- Intraductal-papillary low grade 0 0
11 Stat1-/- Stat1+/+ ductal 2 2 1 1 - 0 1
12 Stat1-/- Stat1+/+ ductal 3 3 2 3 - 4(60%/2) 0
13 Stat1-/- Stat1+/+ intraductal high grade 4(60%/2) 1
14 Stat1+/+ Stat1-/-
ductal/with metaplastic 
features
3 3 2 3 - 0(<10%) 0
15 Stat1+/+ Stat1+/+ ductal 1 1 1 1 - 5(50%/3) 2
16 Stat1+/+ Stat1+/+ ductal 2 2 3 2 - 0 1
17 Stat1+/+ Stat1+/+ ductal 1 1 1 1 low grade 0(<10%) 0
18 Stat1+/+ Stat1+/+ intraductal with microinvasion low grade 0 n.a.
Table I: Histopathological and immunohistochemical analysis and classification of mammary tumors. Histological 
sections of all available mammary tumors were analyzed and mouse mammary tumors characterized according to a standard nomenclature 
used to classify human breast carcinomas. Invasive carcinomas were graded according to Elson and Ellis [20]. 1: well-differentiated breast 
cells, cells generally appear normal and do not grow rapidly, cancer arranged in small tubules; 2: moderately-differentiated breast cells, 
have characteristics between Grade 1 and Grade 3 tumors; 3: poorly differentiated breast cells, cells do not appear normal and tend to grow 
and spread more aggressively. Tubule formation (% of carcinoma composed of tubular structures) – 1: > 75%; 2: 10-75%; 3: less than 10%. 
Nuclear pleomorphism – 1: small, uniform cells; 2: moderate increase in size and variation; 3: marked variation. Mitosis count – 1: up to 
7; 2: 8 to 14; 3: 15 or more. Mammary intraepithelial neoplasia (MIN) – -: not detected; low grade; moderate grade; high grade. Εstrogen 
receptor alpha (ERα) – Reiner score [36], i.e. 0-2: negative; 3: low positive; 4-5: moderate positive; 6-7: strong positive. Human epidermal 
growth factor receptor 2 (HER2) – 0-1: negative; 2: low positive; 3: strong positive.Oncotarget 2011; 2:  1043 - 1054 1050 www.impactjournals.com/oncotarget
glands of wild type, Stat1-/-, Rag2-/- or Stat1-/-Rag2-/- mice. 
As  Rag2-/- animals lack T cells and rely on NK cells 
for tumor surveillance, this experiment allowed us to 
determine the individual contribution of T and NK cells 
to tumor surveillance. The experiment was terminated 
and  tumor  weights  determined  when  the  first  tumors 
reached approximately 1 cm in diameter. The Stat1-/- cell 
line #2 failed to induce tumors in wild-type mice and 
tumor formation was restricted to immuno-compromised 
animals. This observation is consistent with previous 
findings that tumors evolving in immunodeficient hosts 
(such as Stat1-/-) are more immunogenic and not immuno-
edited and may be rejected in immuno-competent 
surroundings [26].
Fig. 4D summarizes the data from orthotopic tumor 
injections.  We  found  a  consistently  and  significantly 
enhanced tumor growth in Stat1-/- mice compared to 
wild-type controls, irrespective of the cell line injected. 
Compared to Rag2-/- animals, tumor growth in Stat1-/- 
or Stat1-/-Rag2-/- hosts was not significantly accelerated, 
indicating that the NK-cell compartment played at most a 
minor part in restricting proliferation of the transplanted 
tumor cells. Support for this conclusion came from a 
comparison of wild-type recipients with Rag2-/- mice. 
Although  Rag2-/- mice contain functionally competent 
NK-cells, tumor growth in these mice was significantly 
increased, indicating that the NK cell compartment was 
not capable of significantly limiting tumor expansion. In 
summary, the data indicate a dominant role for cytotoxic 
T cells in tumor surveillance in spontaneously occurring, 
parity-induced mammary tumors.
Figure 4: Mammary tumor growth is mainly controlled by cytotoxic T-cells and only to a minor extent by NK-cells. 
(A) Histological sections of spontaneously occurring mammary tumors of the transplant experiment were stained with CD3 and NKp46 
antibodies. Tumors are listed in four groups: Stat1+/+ tumors in Stat1+/+ mice, Stat1+/+ tumors in Stat1-/- mice, Stat1-/- tumors in Stat1-/- mice 
and Stat1-/- tumors in Stat1+/+ mice. Scale bars: 100 µm. (B) Bright-field (top panel) and fluorescence (bottom panel) microscopy pictures 
of tumor cell lines derived from two Stat1-/- (#1, #2) and two Stat1+/+ (#3, #4) spontaneous mammary tumors. (Blue) DAPI; (red) STAT1. 
Scale bars: 50 µm. (C) Growth curve of mammary tumor cell lines. (D) Mammary tumor cell lines were orthotopically injected into wt, 
Stat1-/-, Rag2-/- and Stat1-/-Rag2-/- animals. Tumor weights of different groups were compared. n ≥ 5 per genotype. All data are representative 
of two independent experiments.
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DISCUSSION
We show that the transcription factor STAT1 has 
a tumor-suppressing function against the formation of 
parity-induced, spontaneous mammary tumors. We show 
that  STAT1  deficiency  significantly  increases  tumor 
incidence in BALB/c mice as well as decreasing disease 
latency. STAT1 acts in a dual manner. It sustains proper 
CTL activity and thus ensures tumor surveillance, while 
also exerting growth inhibitory and tumor suppressing 
effects via its downstream regulator IRF1.
Our findings are in line with recent reports on the 
role of STAT1 in the context of ERBB2/neu/HER2 
induced mammary cancer development [9, 10]. Using 
different mouse models, both groups concluded that 
STAT1 suppresses ERBB2/neu/HER2 tumor formation. 
In our cohort of mice we characterized tumors that 
evolved spontaneously in the absence of a driving 
oncogene. The fact that only 2/13 of the mammary cancers 
expressed ERBB2/neu/HER2 indicates that STAT1’s 
tumor-suppressing effect is not limited to ERBB2/neu/
HER2-induced tumorigenesis. The effect of STAT1 loss 
is also not restricted to tumors that display a particular 
pattern of expression of the estrogen receptor (ER): 7/13 
of the spontaneously evolving Stat1-/- mammary cancers 
were ER+, while the remaining cases did not express 
detectable levels of the ER protein. These findings show 
conclusively that STAT1 is a global tumor suppressor that 
acts independently of a distinct oncogenic driver.
The importance of STAT1 as a tumor suppressor 
was underlined by the finding that all Stat1+/+ mammary 
cancers had partially lost or down-regulated STAT1 
protein expression. Similar observations were reported 
in human patients, where low levels of STAT1 activation 
have been linked to a poor prognosis [5, 27]. The selection 
pressure to down-regulate or lose STAT1 in tumor cells 
may have more than one cause as the loss of STAT1 has 
several important consequences: the tumor cells lose 
responsiveness towards interferon-mediated growth 
inhibition (interferons are important players in tumor 
surveillance). Moreover, STAT1 is the key regulator of 
MHC class I expression. By losing STAT1 the cells may 
down-regulate MHCI and thus escape CTL-mediated 
tumor surveillance [28, 29]. As NK cells play a negligible 
part in tumor surveillance, MHCI loss represents a clear-
cut  advantage.  CTLs  dominated  the  immune  infiltrate 
in the tumor sections and their importance was further 
verified  in  transplant  studies.  In  the  absence  of  the 
adaptive immune system, tumor development occurred 
rapidly  and  was  significantly  accelerated,  whereas  the 
presence of NK cells did not interfere with tumor onset. 
Hence, mammary tumors are partially able to escape 
immune control by down-regulating STAT1. In Stat1-/- 
animals, the selective pressure to escape immune control 
is less important as the mice have several defects that limit 
their capability to exert effective tumor surveillance. As a 
consequence, mammary cancer formation is increased in 
a Stat1-/- micro-environment, irrespective of whether the 
epithelial cells themselves express STAT1. The finding 
underlines the role of the immune system in spontaneously 
evolving mammary cancer. Although a pro-inflammatory 
environment  and  T-cell  infiltration  may  exert  a  tumor 
promoting effect, our orthotopic injection experiments 
unequivocally show that there is a tumor suppressing 
function that opposes the tumor promoting effect of the 
immune infiltrate. 
Loss or down-regulation of STAT1 confers an 
additional advantage, i.e. accelerated cell proliferation. 
Under normal conditions, STAT1 puts the brakes on cell 
proliferation in mammary epithelial cells, presumably via 
the transcription factor IRF1. Two lines of evidence support 
this assumption. First, whole mounts of Stat1-/- as well as 
of Irf1-/- mammary glands display increased amounts of 
ductal structures compared to wild type controls, even in 
the virgin state. Secondly, BrdU incorporation studies in 
vitro and in vivo confirm an increased DNA synthesis and 
thus enhanced growth in mammary epithelial cells of both 
Stat1-/- and Irf1-/- mice. 
As a consequence of enhanced cell proliferation, 
MIN formation was frequently found in Stat1-/- mice. 
This finding was also reflected in 3D-culture experiments, 
in which the cell composition of Stat1-/- and Irf1-/- acini 
was less organized. The original report describing the 
3D system used the two oncogenes MYC and KrasG12D 
to characterize the occurrence of highly proliferative 
depolarized spheres resembling MIN. As expected, the 
alterations observed in Stat1-/-- and Irf1-/--derived spheres 
are less pronounced than those occurring in the presence 
of  MYC and KrasG12D. In the absence of STAT1 and 
IRF1, polarity of the spheres is preserved and a lumen – 
albeit smaller – is maintained in most cases. Therefore, 
additional alterations are required to allow mammary 
tumor formation. These additional alterations are most 
probably triggered by hormonal stimulation and changes 
occurring during lactation in the breast tissue, as we failed 
to detect spontaneous tumorigenesis in nulliparous mice. 
Our conclusion that STAT1/IRF1 act in a linear axis to 
block growth is in perfect accordance with reports by 
others that attribute a negative regulatory role of IRF1 on 
cell growth: enforced expression of IRF1 in mammalian 
cell lines slows or even halts proliferation [30-32].
Cancer formation is a multi-level process during 
which a cell successively acquires several genetic 
or epigenetic alterations that ultimately cooperate to 
allow the development of a malignant tumor. One of 
the alterations required to initiate the process is loss of 
growth control. Our findings support a model in which 
STAT1 represents a critical safeguard that preserves 
growth control in mammary epithelial cells. The absence 
of STAT1 facilitates cell proliferation and therefore MIN Oncotarget 2011; 2:  1043 - 1054 1052 www.impactjournals.com/oncotarget
formation, which represents the first step on the road from 
normal breast tissue towards invasive breast cancer [33].
The exact characterization of the early alterations has 
a significant potential for use in preventative therapy of 
invasive breast cancer and might lead to the development 
of novel immune-modulatory strategies to combat the 
disease. The critical effect of STAT1 is not restricted to 
any distinct tumor type but is of global relevance. 
MATERIAL AND METHODS
Mice
All animals were maintained in spf quality at the 
University of Veterinary Medicine, Vienna. C.Cg-Stat1tm1 
(Stat1-/-) [16], C.Cg-Irf1tm1Mak (Irf1-/-) [34] and C.129S6-
Rag2tm1Fwa (Rag2-/-) [35] mice have been described 
previously. C.Cg-Stat1tm1-Rag2tm1Fwa (Stat1-/-Rag2-/-) mice 
were crossed at the University of Veterinary Medicine, 
Vienna. Animal experiments were discussed and approved 
by the institutional ethics committee and undertaken in 
conformance with Austrian laws.
Orthotopic injection of mammary tumor cell lines
Mammary tumor cell lines #1-#4 were derived from 
spontaneous mammary tumors. For orthotopic injection 
of mammary tumor cell lines, mice were anaesthetized 
and depilated on the belly. 5x105 cells were injected via 
the nipple into the fat pad of the 4th and 5th mammary 
gland of wild type, Stat1-/-, Rag2-/- and Stat1-/-Rag2-/- mice. 
The mice were sacrificed when the tumors reached one 
centimeter in diameter. 
Histology and immunohistochemistry
The following antibodies were used for 
immunostaining in accordance with to the manufacturers’ 
protocol: STAT1 (Santa Cruz, #sc-592), CD3 (Neomarkers, 
RM9107), NKp46 (BioLegend, #137601), ERα (Santa 
Cruz, #sc-542), CK8 (Developmental Studies Hybridoma 
Bank, TROMA-I) and Ki67 (Novocastra, NCL-Ki67). 
Nuclear counterstaining was performed with hematoxylin. 
Pictures were taken on a Zeiss AxioImager Z1 microscope 
system with a CCD camera using the software PixelNK 
Capture 3.0.
Immunofluorescence
For immunofluorescent staining, cells or 3D cultures 
were incubated with primary antibodies against STAT1 
(Santa Cruz, #sc-592), integrin α6 (Millipore, #MA1378) 
or ZO1 (Zymed Laboratories, #33-9100), followed by 
incubation with Alexa546-conjugated or Alexa488-
conjugated goat antibodies against rat or mouse IgG 
(Molecular Probes, #A11081 and #A11001). Incubation 
times were prolonged for 3D cultures to ensure complete 
staining. Cells were counterstained with DAPI and 
imaged using a confocal laser-scanning microscope (Carl 
Zeiss LSM 700, Occulare 10x, 40x Oil) using the software 
ZEN 2009 LE.
Statistics
All statistical analysis was performed using 
GraphPad Prism 4. Differences were assessed for 
statistical  significance  by  One-way  ANOVA  using  the 
Tukey’s Multiple Comparison Test. For Figure 1B only, 
the unpaired t-test was used. Error bars represent mean ± 
SD. P values are considered as follows: <0.05: *; <0.01: 
**; <0.001: ***. 
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